

Name · AISA Therapeutics

Address/P.O. Box · Genopole Entreprises

4. rue Pierre Fontaine

Postal Code/City · 91058 Evry

Country · France

Contact Person · Patrizia d'Alessio

Telephone + +33-6-87478032

Fax · +33-178400438

Email Address · endocell@wanadoo.fr

endocell@aisa-tx.com

Internet Website · www.aisa-tx.com

www.aisa-care.com

Number of Employees · 3

Founded (year) · 2005

Type of Laboratory · Biocell

Areas of Activity · Nutraceutical & drug R&D

Relevant R&D Budget · €3 m

Biological Patents · 3 granted patents EU, US & China

External · Academic and CRO

Collaborations

Request for · Marketing & Distributors Further Collaborations in EU. US & ASIA

The company

AISA Therapeutics was spun out of a fundamental research on novel anti-inflammatory molecules (René Descartes University 5 Paris Necker-Children's Hospital and University Paris Sud-11) by Patrizia d'Alessio. She identified and patented four plant molecules out of 2000, using an in vitro bio-guided research. In 2007, one of these molecules (AISA 5203-L) gave rise, following pre-clinical evaluation on oral and topic administration, to two new patents covering the treatment of stress and tissue repair in skin and colon.

Achievements and recent developments

The company is developing its hit AISA 5203-L (three patents filed, the first one granted in Europe and the US, the third granted in Europe, the US and China, evaluation ongoing for the second in Europe and the US). Preclinical studies have revealed AISA 5203-L anti-inflammatory effects in the skin and colon, as well as its anti-stress properties (dopamine boost). Clinical studies on AISA 5203-L were hosted by the EU project Ristomed, validating the anti-inflammatory and anti-stress effects on healthy elderly people aged from 65 to 85. The expected impacts of AISA 5203-L to lower circulating levels of the inflammatory markers (inhibition of IL-6) and to modulate stress (anxiety) have been confirmed.

Relying on its preclinical and clinical results, AISA Therapeutics has developed new products that will be on the market at www.aisa-care.com under the brand AISA moleculum®.

 AISA moleculum® for oral administration: bio natural soft gel capsules guarantee the inhibition of IL-6, responsible for silent inflammation, insomnia and chronic mood disorders. The mood-soothing virtues of AISA 5203-L have been measured. It improves performance with a subtle but energising effect that results in enhanced well-being. AISA scientific articles are available on www.aisa-tx.com



Moreover, in a exploratory study for psoriasis of intermediate severity, AISA moleculum® was given orally and administered topically (using the same concentration of the active compound as contained in the soft gel capsules) showing a resolution of the symptoms (published in GJDV in 2015).

- · AISA moleculum® for topic dermatologic administration: AISA 5203-L has been also tested in dermatologic tests proving its high anti-wrinkle and antiageing potential. The tests were based on the reenforcement of the intrinsic elasticity of the skin and a very high hydration factor (14%). Three different products are presented in the form of a mist by the Wpe/Ultradrops® (published in PRIME International in 2015).
- "La Brume" for topic dermo-cosmetic administration: the mist contains bio extracts from orange peel, which guarantee hydration and skin elasticity as well as a visible and continuous anti-ageing effect.

The ways AISA Tx will solve the major problems of this market are:

- availability of the natural ingredients (stock of raw materials)
- purity (toxicological proof beyond bio labelling)
- evidence-based medicine ingredients efficacy
- evidence-based medicine ingredients mechanism of action

Current needs

In order to finalise the launch of its first medically prescribed products, to be purchased in pharmacies, the company has researched the areas of marketing and distribution, as well as launching a website dedicated to the products: www.aisa-care.com